Ticker
AADI

Price
8.19
Stock movement up
+0.06 (0.74%)
Company name
Aadi Bioscience Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
199.80M
Ent value
89.98M
Price/Sales
18.18
Price/Book
1.18
Div yield
-
Div growth
-
Growth years
-
FCF payout
-4.62%
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-50.54%
3 year return
-68.46%
5 year return
-60.08%
10 year return
-
Last updated: 2023-06-06
Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ETCompany ParticipantsMarcy Graham - Senior Vice President of Investor Relations and...
May 10, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
May 10, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

AADI does not pay dividends or no data was received
Loading...
AD

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales18.18
Price to Book1.18
EV to Sales8.19
Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
May 9, 2023

iO Charts is a Seeking Alpha partner

Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q4 2022 Earnings Conference Call March 28, 2023 8:30 AM ETCompany ParticipantsMarcy Graham - Senior Vice President of Investor Relations and...
March 28, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count24.40M
EPS (TTM)-2.94
FCF per share (TTM)-3.84

Income statement

Loading...
Income statement data
Revenue (TTM)10.99M
Gross profit (TTM)10.00M
Operating income (TTM)-63.16M
Net income (TTM)-62.59M
EPS (TTM)-2.94
EPS (1y forward)-2.53

Margins

Loading...
Margins data
Gross margin (TTM)90.96%
Operating margin (TTM)-574.71%
Profit margin (TTM)-569.57%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash134.81M
Net receivables2.26M
Total current assets189.86M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets194.10M
Accounts payable3.92M
Short/Current long term debt1.72M
Total current liabilities17.89M
Total liabilities25.00M
Shareholder's equity169.11M
Net tangible assets169.11M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-80.89M
Capital expenditures (TTM)676.00K
Free cash flow (TTM)-81.57M
Dividends paid (TTM)3.77M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-37.01%
Return on Assets-32.25%
Return on Invested Capital-36.93%
Cash Return on Invested Capital-48.13%
Loading...
AD

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open8.13
Daily high8.36
Daily low8.05
Daily Volume83K
All-time high1485.00
1y analyst estimate42.50
Beta-
EPS (TTM)-2.94
Dividend per share-
Ex-div date-
Next earnings date8 Aug 2023

Downside potential

Loading...
Downside potential data
AADIS&P500
Current price drop from All-time high-99.45%-10.40%
Highest price drop-99.54%-56.47%
Date of highest drop28 Mar 20239 Mar 2009
Avg drop from high-77.12%-11.53%
Avg time to new high75 days13 days
Max time to new high1389 days1805 days
The following slide deck was published by Aadi Bioscience, Inc.
March 28, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
March 28, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
AADI (Aadi Bioscience Inc) company logo
Marketcap
199.80M
Marketcap category
Small-cap
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Employees
76
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
March 27, 2023

iO Charts is a Seeking Alpha partner

Aadi Bioscience is a commercial stage company with a potential label expansion ahead. Click here to learn why I rate AADI stock a Buy.
March 7, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
March 3, 2023
Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ETCompany ParticipantsMarcy Graham - Senior Vice President of Investor Relations &...
November 9, 2022
Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
November 9, 2022
Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
November 8, 2022
The following slide deck was published by Aadi Bioscience, Inc.
November 3, 2022
Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
October 12, 2022
The following slide deck was published by Aadi Bioscience, Inc.
September 30, 2022
Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
September 22, 2022
Aadi Bioscience shares lost half their value since reverse merger with Aerpio Pharmaceuticals. Click here to read why AADI stock is a Buy in my view.
September 21, 2022
Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ETCompany ParticipantsMarcy Graham - SVP of IR and Corporate CommunicationsNeil Desai -...
August 10, 2022
iO Charts is a Seeking Alpha partnerNext page